top of page

Interventional retrospective case series of patients undergoing treatment intervals of more than twenty-four (24) weeks with faricimab


Adrian Babel


Adrian Babel MS1,4, Eric K. Chin MD2,3 & David Almeida, MD MBA PhD4

1. Boonshoft School of Medicine, Dayton, OH, USA

2. Retina Consultants of Southern California, Redlands, CA, USA

3. Loma Linda Eye Institute; Veterans Affair Hospital, Loma Linda, CA, USA

4. Erie Retina Research & Center for Advanced Surgical Exploration, Erie, PA, USA


Purpose: To evaluate the efficacy of intravitreal faricimab dosing interval at and beyond twenty-four (24) weeks in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).


Methods: Retrospective case series of six (6) patients with persistent DME and nAMD who received intravitreal faricimab at and beyond the 24-week (six-month) dosing interval regimen.


Results: The majority of patients experienced improved vision (mean best-corrected visual acuity (BCVA) improvement of 10.5 letters) and anatomy (mean central macular thickness (CMT) decrease of 37.667μm on optical coherence tomography (OCT)) at 6 months despite extended faricimab dosing intervals.


Conclusions: Extended intravitreal faricimab dosing intervals at and beyond 24 weeks maintained visual and anatomical outcomes in patients over 6 months. This suggests the feasibility of personalized extended dosing tailored to each patient’s disease activity, potentially reducing treatment burden.

bottom of page